3-(5-chloro-6-methoxy-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 3-(5-chloro-6-methoxy-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid
• 英文别名: 3-(5-chloro-6-methoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid；3-(5-Chloro-6-methoxy-2-oxo-1,3-benzoxazol-3-yl)propanoic acid；3-(5-chloro-6-methoxy-2-oxo-1,3-benzoxazol-3-yl)propanoic acid
• 化学式: C₁₁H₁₀ClNO₅
• 分子量: 271.657
• InChiKey: ULGMFNQVPOXZSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-amino-4-chloro-5-methoxyphenol 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 4.0h， 生成 3-(5-chloro-6-methoxy-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid
  参考文献：
  名称：

  一系列Kynurenine 3-Monooxygenase抑制剂的开发导致治疗急性胰腺炎的临床候选药物

  摘要：

  最近，我们报道了KMO在急性胰腺炎（AP）发病机理中的新作用。犬尿氨酸3-单加氧酶（KMO）的许多抑制剂以前已被描述为神经退行性疾病，尤其是亨廷顿舞蹈病的潜在治疗方法。然而，迄今为止报道的抑制剂相对于其细胞效力而言，其水溶性不足以与AP中所需的静脉内（iv）给药途径相容。我们已经鉴定并优化了一系列具有良好理化特性的新型高亲和力KMO抑制剂。最主要的例子是选择性强，在两个物种中清除率低，在急性胰腺炎的大鼠模型中预防肺和肾脏的损害，并正在向临床前发展。

  DOI：

  10.1021/acs.jmedchem.7b00055

文献信息

• [EN] 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOÏQUE EN TANT QU'INHIBITEURS DE LA KMO
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015091647A1

  公开（公告）日：2015-06-25

  A compound of formula (I) or a salt thereof are provided wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

  提供了一种公式(I)的化合物或其盐，其中R1、X和R3如说明书中所定义，用于治疗由KMO介导的疾病，如急性胰腺炎、慢性肾病、与其他系统性炎症反应综合征(SIRS)相关的条件、亨廷顿病、阿尔茨海默病、脊髓小脑共济失调、帕金森病、艾滋病痴呆复合体、肌萎缩侧索硬化(ALS)、抑郁症、精神分裂症、败血症、心血管休克、严重创伤、急性肺损伤、急性呼吸窘迫综合征、急性胆囊炎、严重烧伤、肺炎、大手术程序、缺血性肠病、严重急性肝病、严重急性肝性脑病或急性肾衰竭。
• 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors
  申请人：THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH

  公开号：US11352334B2

  公开（公告）日：2022-06-07

  A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

  提供了式 (I) 的化合物或其盐： 其中 R1、X 和 R3 在说明书中定义，可用于治疗由 KMO 介导的疾病，如急性胰腺炎、慢性肾脏病、与全身炎症反应综合征（SIRS）相关的其他疾病、亨廷顿氏病、阿尔茨海默病、脊髓小脑性共济失调、帕金森氏病、艾滋病-痴呆综合症淀粉样变性脊髓侧索硬化症（ALS）、抑郁症、精神分裂症、败血症、心血管休克、严重创伤、急性肺损伤、急性呼吸窘迫综合征、急性胆囊炎、严重烧伤、肺炎、大面积外科手术、缺血性肠道、严重急性肝病、严重急性肝性脑病或急性肾功能衰竭。
• 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3083574A1

  公开（公告）日：2016-10-26
• 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL) PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20160318884A1

  公开（公告）日：2016-11-03

  A compound of formula (I) or a salt thereof are provided: wherein R 1 , X and R 3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
• Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis
  作者：Ann L. Walker、Nicolas Ancellin、Benjamin Beaufils、Marylise Bergeal、Margaret Binnie、Anne Bouillot、David Clapham、Alexis Denis、Carl P. Haslam、Duncan S. Holmes、Jonathan P. Hutchinson、John Liddle、Andrew McBride、Olivier Mirguet、Christopher G. Mowat、Paul Rowland、Nathalie Tiberghien、Lionel Trottet、Iain Uings、Scott P. Webster、Xiaozhong Zheng、Damian J. Mole

  DOI：10.1021/acs.jmedchem.7b00055

  日期：2017.4.27

  Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A number of inhibitors of kynurenine 3-monooxygenase (KMO) have previously been described as potential treatments for neurodegenerative conditions and particularly for Huntington’s disease. However, the inhibitors reported to date have insufficient aqueous solubility relative to their cellular potency to be compatible

  最近，我们报道了KMO在急性胰腺炎（AP）发病机理中的新作用。犬尿氨酸3-单加氧酶（KMO）的许多抑制剂以前已被描述为神经退行性疾病，尤其是亨廷顿舞蹈病的潜在治疗方法。然而，迄今为止报道的抑制剂相对于其细胞效力而言，其水溶性不足以与AP中所需的静脉内（iv）给药途径相容。我们已经鉴定并优化了一系列具有良好理化特性的新型高亲和力KMO抑制剂。最主要的例子是选择性强，在两个物种中清除率低，在急性胰腺炎的大鼠模型中预防肺和肾脏的损害，并正在向临床前发展。